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ABSTRACT
Conventional fluid-bed and immersion film coating of hydrophilic zinc pectinate 
spheroids using ethylcellulose-pectin mixture is met with fast drug release due to 
hydrophobic ethylcellulose coat detachment. This study explored in situ intra-capsular 
spheroid coating for colon-specific delivery of 5-fluorouracil. The solid coating powder 
was constituted of ethylcellulose and pectin in weight ratios of 11:0 to 2:9. Its weight 
ratio to spheroids was varied between 2:3 and 3:2. Delayed 5-fluorouracil release was 
obtained when the weight ratio of ethylcellulose and pectin in coating powder was kept at 
8:3, and weight ratio of solid coating powder to spheroids was kept at 3:2 with particle 
size of ethylcellulose reduced to 22 ^m. In situ intra-capsular wetting of pectin coat by 
dissolution medium resulted in the formation of ethylcellulose plug interconnecting with 
spheroids through the binding action of pectin. The majority of drug was released in the 
colon region and complete drug release was obtained through digestion of core spheroids 
by pectinase. Through in vivo pharmacokinetic and pharmacodynamic studies, the intra- 
capsular coated spheroids were found to be able to reduce the drug bioavailability, 
enhance its accumulation at colon and reduce both number and size of tumor through 
reforming the tubular epithelium with basement membrane and restricting the expression 
of cancer from adenoma to adenocarcinoma. Given a dosage regimen of 15 mg/kg/day for 
5 days in rats, the intra-capsular coated spheroids also eliminated the formation of 
aberrant crypt foci which represented a putative preneoplastic lesion in colon cancer, 
unlike other treatment modes. Inferring from blood levels of hemoglobin, red blood cell, 
white blood cell, hematocrit, mean corpuscular hemoglobin, platelet, urea, creatinine, 
alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase and bilirubin, 
intra-capsular spheroid coating to target 5-fluorouracil delivery at cancerous colon is 
concluded as a feasible colon cancer formulation approach with reduced risks of systemic 
adversity.
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CHAPTER ONE
INTRODUCTION
1.1 OVERREVIEW
The occurrence of cancer could rise by 50 % to 15 million new cases in the year o f 2020, 
in accordance to World Cancer Report of which represents the most comprehensive 
global examination outcome to date [1]. Colon cancer refers to cancerous growth in 
colon, rectum or cecum [2]. It accounts for 940,000 new cases annually, following lung 
and breast cancers with annual 1.2  million and just over 1 million new cases respectively 
[1]. Colon cancer is reckoned to be a disease of affluence and occurs most frequently in 
North America, Australia, New Zealand, Japan and Western Europe [3-7]. A total of
639,000 deaths related to colon cancer are reported worldwide each year.
Surgery remains the primary mode of colon cancer treatment with chemotherapy and/or 
radiotherapy recommended upon the nature and extent of severity of disease [2 ]. 
Chemotherapy can be provided after surgery as adjuvant, before surgery as neo-adjuvant 
or as primary therapy to reduce tumor size and growth as well as the likelihood or 
propensity of metastasis. 5-fluorouracil (5-FU) is one of the common drugs used as colon 
cancer chemotherapeutic [8,9], It is a thymidylate synthase inhibitor which primarily 
interrupts the synthesis of pyrimidine thymidine, a nucleoside required for 
deoxyribonucleic acid replication, through depleting thymidine monophosphate. This then 
results in rapidly dividing cancerous cells undergoing thymine less cell death.
Oral colon-specific drug delivery can be mediated by means of prodrugs, azo-polymers, 
time-, pH- and pressure-sensitive, as well as, microbial-activated approaches [10-15]. To 
succeed in colon targeting, it is imperative to deliver drugs at an adequate local 
concentration and without premature drug release/loss in the upper gastrointestinal tract. 
The spheroids and microparticles are preferred oral dosage forms for delivery of 
chemotherapeutic agents to the target sites of colon cancer [2]. Unlike gastric transit, 
small dosage forms show a slower colon transit than large dosage forms [10]. Prolonged 
colonic retention of dosage form and/or consistent local colonic exposure to anti-cancer
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